EGFR/ALK/ROS1 (EAR) Mutation Detection Kit

EGFR, ALK, and ROS1 are the most common molecular targets for targeted therapies in a subset of patients with non-small cell lung cancer (NSCLC). EGFR mutations and ALK, and ROS1 gene fusions have been shown to be effective therapeutic targets of tyrosine kinase inhibitors (TKIs). The EGFR/ALK/ROS1 (EAR) Mutation Detection Kit is capable to detect 24 EGFR mutations (exons 18-21), 21 ALK gene fusions, and 13 ROS1 gene fusions.


EGFR, ALK, and ROS1 are the most common molecular targets for targeted therapies in a subset of patients with non-small cell lung cancer (NSCLC). EGFR mutations and ALK, and ROS1 gene fusions have been shown to be effective therapeutic targets of tyrosine kinase inhibitors (TKIs). The EGFR/ALK/ROS1 (EAR) Mutation Detection Kit is capable to detect 24 EGFR mutations (exons 18-21), 21 ALK gene fusions, and 13 ROS1 gene fusions.